URSODEOXYCHOLIC ACID MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America has established itself as the dominant region in the global ursodeoxycholic acid market with an estimated market share of 40.3% in 2024, owing to high prevalence of liver and gallbladder disorders in the U.S. and Canada. Moreover, strong presence of leading pharmaceutical companies in the region engaged in the production of ursodeoxycholic acid and its formulations has boosted manufacturing capacity. These companies have also undertaken various clinical trials to expand the therapeutic application of ursodeoxycholic acid, which has increased its consumption.

In terms of pricing, North America commands a premium in the global market due to high purchasing power of consumers and dominant market position of regional players. The import of ursodeoxycholic acid formulations is restricted through strategic agreements to ensure steady supply for domestic players. Exports from the region have also increased with the approval of new drug applications in international markets.

Asia Pacific has emerged as the fastest growing regional market for ursodeoxycholic acid. Countries like China, India, Japan, and South Korea are majorly contributing to the rapid growth of the Asia Pacific market. This can be attributed to rising geriatric population, increasing healthcare expenditure, and growing awareness regarding liver disorders in the region.

The market growth is driven by improving accessibility of ursodeoxycholic acid drugs due to favorable governmental policies and subsidies. Regional manufacturers are focusing on capacity expansion to cater to rising demand from the domestic market. Growing imports from European and North American markets to meet the shortfall in supply have complemented the market growth. These trends are anticipated to favor the Asia Pacific region to outpace other regions in terms of future demand.